Oncotelic Therapeutics Announces Opening of GMP Manufacturing Plant
AGOURA HILLS, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) — Oncotelic Therapeutics, Inc (OTCQB:OTLC) (“Oncotelic”, the “Company” or “We” or “Our”), unveils a state-of-the-art GMP Manufacturing Plant, a significant stride in biopharmaceutical innovation, through its joint venture Sapu Biosciences LLC. Situated in San Diego biotechnology hub, this cutting-edge, AI-driven facility marks a pivotal expansion in the company’s clinical pipeline, advancing beyond its OT-101 development. Discover more at https://sapubio.com/contact/.”
Related news for (OTLC)
- Product Manager Scott Myers to Present at 2nd Global Summit on Artificial Intelligence
- ONCOTELIC TO PRESENT AT THE 20TH ANNUAL CONGRESS OF INTERNATIONAL DRUG DISCOVERY SCIENCE & TECHNOLOGY
- ONCOTELIC TO PARTICIPATE AT THE BIO INTERNATIONAL 2024 MEETING
- ONCOTELIC TO PARTICIPATE AT THE ASCO 2024 MEETING
- Linkage of Cancer and Lupus in Gliomas Patients